# A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris

> **NCT01016977** · PHASE4 · COMPLETED · sponsor: **Stiefel, a GSK Company** · enrollment: 40 (actual)

## Conditions studied

- Acne Vulgaris

## Interventions

- **DRUG:** Clindamycin 1%/Benzoyl Peroxide 5% and 0.1% tazarotene
- **DRUG:** clindamycin phosphate 1.2%/benzoyl peroxide 2.5% and 0.1% tazarotene

## Key facts

- **NCT ID:** NCT01016977
- **Lead sponsor:** Stiefel, a GSK Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2017-01-30

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01016977

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01016977, "A Phase 4, Single-Blind, Randomized, Study to Compare the Tolerability and Efficacy of 0.1% Tazorac Cream When Used in Combination With Either Duac Gel or Acanya Gel for the Treatment of Facial Acne Vulgaris". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01016977. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*